INTRODUCTION
Hypertension is increasingly recognised as an important disease in childhood. Hypertension is diagnosed in childhood, according to the National High Blood Pressure Group 2004, when an average systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) is found to be on the 95th percentile or above for age, gender and height on at least three separate occasions. 1 It is widely accepted that early identification and treatment of hypertensive children may possibly prevent the development of established hypertension and its complications in adulthood. 2 3 ACE inhibitors have the power to restore the balance between two endogenous systems that are predominantly affected in the pathogenesis of hypertension in childhood: the renin-angiotensin system (RAS) and the kallikrein-kinin system. 4 Blocking of ACE induces a decrease in systemic vascular resistance, an increase in renal plasma flow and stimulates salt excretion, making ACE inhibitors potent antihypertensive therapies. Furthermore, ACE inhibitors have demonstrated in adulthood to have a renoprotective potency in adulthood by first inducing vasodilatation of the efferent arteriole and decreasing the filtration pressure, and thus the degree of proteinuria. Second, they suppress local growth and inflammatory factors, subsequently leading to a reduction of glomerular hypertrophy, sclerosis, tubulointerstitial inflammation and fibrosis. 4 Since hypertension in childhood is most frequently secondary to a renal parenchymal disease, ACE inhibitors are recognised as very useful antihypertensive therapies in the paediatric population. Adverse effects that patients treated with ACE inhibitors can encounter are hypotension, cough, hyperkalaemia, acute kidney injury, fetal anomalies and angioedema. Neutropenia, rash and nephrotic-range proteinuria are adverse events (AEs) especially related to the sulfhydryl group of captopril. 4 In patients with volume depletion, bilateral renal artery stenosis or unilateral renal artery stenosis in a single kidney, an ACE inhibitor can induce an important drop in glomerular filtration rate (GFR). 4 ACE inhibitors are one of the prototype drugs targeted by strong incentives introduced worldwide to improve access to safe and effective medicines addressing the therapeutic needs of children. 5 In 1997, the USA launched the pioneering legislation that aimed to promote drug licensing and labelling for children: the 'Food and Drug Administration (FDA) Modernization Act', followed by the 'Best Pharmaceuticals for Children Act' in 2002, the 'Research Equity Act' in 2003 and the FDA Amendments Act and the FDA Safety and Innovation Act in 2012. In 2007, the European Union's Paediatric Regulation and the World Health Assembly of Resolution WHA60.20 followed, based on the US experience. These incentives resulted in an increased number of published clinical trials in hypertensive children. In 2014, the first comprehensive Cochrane review about pharmacological interventions in hypertensive children was published evaluating randomised controlled trials (RCTs) with antihypertensive therapies, including ACE inhibitors. 6 However, only four trials evaluating enalapril, lisinopril and fosinopril were included and the review was not believed to be robust enough to provide firm recommendations for first-line agents in children with hypertension. 6 As a consequence in clinical practice, the selection of the most appropriate ACE inhibitor therapy in children remains a challenge and many clinical questions continue to exist. Our purpose in assembling this review was to evaluate and describe all the current evidence for the efficacy and safety profile of ACE inhibitors in the paediatric hypertensive population and with it to formulate the remaining questions.
MATERIALS AND METHODS
A literature search was performed in PubMed, including abstracts from 1980 to April 2015. Search terms included hypertension, child, paediatric, ACE (inhibitors), RAS and kallikreinkinin system, and following drugs: captopril, lisinopril, enalapril, ramipril and fosinopril. We then continued with the 'snowball method' by looking for references in recent publications and reviews. All intervention studies and observational studies on efficacy and safety of ACE inhibitors in hypertensive children (0-18 years) were included in this review. Trials not published in English, editorial pieces and opinions were excluded. The studies were analysed and the following information was collected: design, number of patients, age, ACE inhibitor, dose, formulation, intervention, primary and secondary end points, antihypertensive events and AEs. To assess the risk of bias of the included studies, we used the Newcastle-Ottawa Scale (NOS) for cohort studies, evaluating the selection of the study groups, the comparability of the groups and the ascertainment of the outcome of interest. 7 The Cochrane Collaboration's tool for assessing risk of bias was used to evaluate randomised studies by scoring sequence generation, allocation concealment, blinding, incomplete or selective outcome reporting and others. 8 
RESULTS
A total of 16 studies evaluating efficacy and safety of ACE inhibitors in the paediatric hypertensive population were included in this review (see table 1 ). [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] To explore the differences between ACE inhibitors, the studies were grouped according to the evaluated ACE inhibitor: captopril (7), lisinopril (3), enalapril (2), fosinopril (1) and ramipril (3). [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Most of the studies were cohort studies with retrospective or prospective data collection. So far four double-blind RCTs have been published. 15 17-20 Three of them (lisinopril, enalapril and fosinopril) were developed according to a type C design, including initial randomisation, followed by two or more active treatment arms (eg, low, medium and high dosage), a second randomisation to double-blind withdrawal to placebo, and an open-label 'safety' phase. 15 17 19 20 The ESCAPE trial, evaluating the time to 50% decrease in GFR or progress to end-stage renal disease (ESRD) in intensified versus conventional blood pressure (BP) control with ramipril treatment, used a prospective open-label RCT design. 24 The quality of the included RCT was very variable. Using the Cochrane Collaboration's tool, the risk of bias was low for sequence generation, blinding and incomplete outcome data in only 2/5 trials. Information about allocation concealment was only available for one study. Assessment of selective outcome reporting was considered low in all included RCTs. Three of the included studies were supported by the industry. 15 18-20 Except for the prospective cohort studies of ramipril, 22 25 the risk of bias (NOS≥6) in the cohort studies was considered to be high.
Different definitions of hypertension were used in the studies. Two of the studies defined hypertension as a DBP of ≥95th percentile for age, gender and height on repeated measurements, according to the 'Fourth Report'. 1 15 17 In contrast, an SBP of ≥95th percentile was used in two studies, and an SBP or a DBP of ≥95th percentile was used in three studies. 14 16 18-20 Soergel et al, 21 Seeman et al 25 and Wühl et al 22 , 24 defined hypertension as 24-hour mean systolic or diastolic arterial pressure ≥95th percentile for age, gender and height. The proportion of children with primary or secondary hypertension varied highly between studies. Additionally, the fosinopril trial included children with high-normal SBP or DBP, which were not included in other trials. 19 20 In contrast, captopril and ramipril were exclusively evaluated in children with hypertension secondary to renal disease. 9-13 21 22 24 The GFR ranged from 11 to >90 mL/ min/1.73 m² and two studies included also children on dialysis. 11 26 Children with a GFR of <30 mL/min/1.73 m² were excluded in five studies. 15 17-20 26 Except for the study of Mirkin et al 12 and Callis et al, 26 children with severe hypertension were always excluded from the studies.
The age range of the patients included varied from premature infant to adolescents. Most of the studies were performed in children ≥3 years. No RCT has been performed in children <6 years. 15 17-20 Captopril was the only ACE inhibitor evaluated in neonates and premature infants (>25 weeks of gestational age). 9 14 All included studies applied a weight-based dose strategy for dose determination and a dose-ranging study design was used in four trials. 15 17-20 Only few reports documented the formulation of the ACE inhibitor used in the study: suspension forms were evaluated for enalapril and tablets were used in nine studies. 9 12 15-20 22-24 The follow-up period of the participants varied widely from 3 days to 6.1 years.
Beside the ESCAPE trial, all studies used BP as their primary outcome variable. In contrast, the ESCAPE trial used the time to 50% decrease in GFR or progress to ESRD in intensified versus conventional BP control with ramipril. 24 The majority of the studies used SBP with or without the combination of DBP as their primary outcome variable. 9-14 16-22 Only the lisinopril RCT used DBP as their primary outcome variable. 15 Most of the studies determined BP auscultatory, 24 hours ambulatory blood pressure measurement (ABPM) was used in four studies. 18 21 22 24 25 
Therapeutic efficacy Captopril
Captopril, the first ACE inhibitor studied in the paediatric population, has been evaluated in seven small studies including children with hypertension due to renal disease.
9-14 26 Mirkin et al 12 published the largest prospective study of 73 children treated with captopril, and a significant reduction in BP was found, with a normalisation of the DBP and SBP after 6 months in 45% and 53%, respectively. Similar BP reduction was found in four other studies. 10 11 13 26 Captopril was shown to be an effective antihypertensive agent in neonates (n=20) of >25 weeks of gestational age with a greater potency than in older children. 9 14 Lisinopril Efficacy of lisinopril has been evaluated in one RCT of 115 hypertensive children that found a clear dose-related response of −0.28 mm Hg per unit increase in dose ratio in sitting DBP in the middle-dose and high-dose group. 15 Lisinopril administration in hypertensive children has also been evaluated in a retrospective study and was found to result in a decrease in both SBP and DBP. 16 The efficacy of lisinopril has also been evaluated in children with a renal transplant in a 30-day pharmacokinetic study and was also found to decrease both SBP and DBP with ≥6 mm Hg in 85% and 77%, respectively. 23 
Enalapril
The efficacy of enalapril has been studied in two large doubleblind RCTs, evaluating 110 and 281 hypertensive children, respectively.
17 18 Wells et al 17 found a linear dose-response To assess the risk of bias of the included studies, the NOS was used for cohort studies, evaluating selection of the study groups, the comparability of groups and ascertainment of the outcome of interest. 7 The Cochrane Collaboration's tool for assessing risk of bias was used to evaluate for randomised studies, scoring sequence generation, allocation concealment, blinding, incomplete or selective outcome reporting and others. 8 . ABPM, ambulatory blood pressure measurement; ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CKD, chronic kidney disease; DBP, diastolic blood pressure; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HT, hypertension; MAP, mean arterial blood pressure; max, maximum; NICU, neonatal intensive care; n, number; ND, not defined; NOS, Newcastle-Ottawa Scale; PK, pharmacokinetics; SBP, systolic blood pressure; Tx, transplantation.
ratio, more specifically a decrease of 0.3 mm Hg in DBP per unit increase in dose ratio, and a significant mean difference in DBP of 6.1±2 mm Hg between the three groups of enalapril compared with placebo. Schaefer et al 18 compared valsartan with enalapril in an active-controlled RCT and found that both drugs were equally effective in reducing BP compared with baseline. In the subgroup of children that had a 24-hour ABPM, valsartan was found to provide a significant greater mean arterial SBP reduction than enalapril. 18 
Fosinopril
Fosinopril has been studied in one placebo-controlled RCT with 253 children with hypertension or a high normal BP. 19 20 The three evaluated doses of fosinopril were found to be equally effective in lowering SBP. 19 20 However, a significant doseresponse was found in black children, which was absent in nonblack children, indicating that black children may need higher doses per body weight. 20 In this study population, 40-60% of the children reached BP control and a decrease of −13/−8.3 mm Hg in BP was reached at 52 weeks follow-up.
Ramipril
Soergel et al 21 and Seeman et al 25 prospectively followed 14 and 31 children respectively taking ramipril and found a significant decrease in both SBP and DBP and nocturnal dipping. In the interim analysis of the ESCAPE trial, evaluating 352 children with chronic kidney disease after 6 months treatment with ramipril, a significant decrease in mean SBP of 11.6 mm Hg and a greater decrease in SBP was shown in children with a GFR of <40 mL/min/1.73 m². 22 In the final analysis of the ESCAPE trial, 385 children were randomised to intensified (<p50) or conventional ( p50-p90) BP control to compare the time until they lose ≥50% in GFR or they progress to ESRD. 24 This primary end point was reached in respectively 41.7% versus 29.9% of the children. Intensified BP control was found to have a 35% lower risk to lose ≥50% in GFR or progress to ESRD. 24 
Safety profile of ACE inhibitors
The short-term safety profile of lisinopril, enalapril and fosinopril in children 6-16 years was evaluated in detail; however, long-term safety data are lacking. Ramipril and captopril are the only ACE inhibitors in which the safety profile has been evaluated over a period of ≥5 years. All the AEs, included in the studies evaluating ACE inhibitors, are summarised in table 2. Since the study design (retrospective vs prospective), the duration of follow-up and the characteristics of the study populations (age, comorbidities, renal function) were very different, comparison between the different ACE inhibitors is difficult.
Dizziness, vertigo, postural symptoms and headache were frequently reported as AEs, especially in the enalapril and fosinopril trials. [17] [18] [19] [20] The incidence of hypotension in the captopril studies was remarkably high in contrast to the other ACE inhibitors. [9] [10] [11] [12] [13] [14] The incidence of increased creatinine and/or blood urea nitrogen (BUN) varied among the different trials from absent to 62% in the study of Sinaiko et al. 10 The ESCAPE trial, including only children with chronic kidney disease (GFR 11-80 mL/min/1.73 m²), reported an increase in creatinine in 50 of the 385 participants of the study population. 24 The incidence of cough in the studies was widely different between the studies but was remarkably lower than in the adult studies, which report cough in almost 20% of the participants. 27 Angioedema has not been reported in these studies.
Only a few serious AEs were reported in the included studies: acute kidney injury in one child with an underlying renal arteria stenosis receiving captopril and one child receiving enalapril, severe hypotension with oliguria in one neonate receiving captopril, haemorrhagic infarction in one neonate receiving captopril and avulsion fracture in one child receiving enalapril. 9 13 18 No related deaths were reported after receiving ACE inhibitors.
DISCUSSION
Thanks to the initiatives of the USA, Europe and the WHO, an overall increase in clinical trials evaluating the efficacy and safety of ACE inhibitors occurred. Overall, ACE inhibitors have demonstrated to have the potency to decrease the SBP and/or DBP with an overall favourable safety profile in a short-term period. More importantly, paediatric labelling by the FDA Reports was obtained for three of the five discussed ACE inhibitors in the paediatric hypertensive population: lisinopril (for children ≥6 years), enalapril (for children ≥1 month) and fosinopril (for children ≥6 years). 28 However, is it really true that the promising legislative initiatives and the improved paediatric labelling narrowed the gap between the availability of ACE inhibitors labelled and indicated for paediatric use and the actual drug usage in children? Welch et al 29 reported that still 25.5-33.1% of the children are receiving unlabelled or not indicated antihypertensive medications. Furthermore, they report that still 7% of all the prescribed antihypertensive drugs were prescribed 'off-label' in children, with neither FDA-approved paediatric label information nor dosing recommendations in the Fourth Report. The risks of 'off-label' use are generally accepted and recently highlighted by Wharton et al, 30 which demonstrated that a quarter of the drugs that received new paediatric labelling obtained a new paediatric safety signal. Furthermore, the recently published Cochrane review evaluating the efficacy and safety of antihypertensive therapies, including ACE inhibitors, could only include four studies evaluating lisinopril (1), enalapril (2) and fosinopril (1) in the analysis. 6 15 17-20 Since trials comparing an ACE inhibitor directly to placebo are lacking, ACE inhibitors were not included in the meta-analysis. Consequently, the Cochrane review failed to provide firm recommendations for ACE inhibitors in the paediatric hypertensive population. 6 Therefore, we assumed to summarise all the current evidence available on ACE inhibitors in the paediatric population in this review, including also non-randomised studies. Although we recognise that the majority of these non-randomised studies were of low quality with high risk of bias, they are currently the only studies reporting about the use of ACE inhibitors in high-risk populations (neonates, young children, children with renal transplant, chronic kidney disease, ESRD, etc) in contrast to the highly selected mild hypertensive population in RCT.
Although the efficacy and safety profile and labelling status of ACE inhibitors improved over time, they still do not meet with the true clinical relevance and several obstacles have to be conquered. First, we have to realise that the efficacy of ACE inhibitors is only evaluated based on BP, a surrogate outcome variable and the proof of efficacy of ACE inhibitors on hard outcome variables such as end-organ damage, cardiovascular morbidity or mortality in adulthood is completely lacking. Also, the use of 24-hour ABPM in clinical trials was poor. Furthermore, the studies evaluated ACE inhibitors only in a short period and the long-term effect and safety of ACE inhibitors on growth, pubertal development and maturation is still unknown.
A second important limitation of these studies is the incomplete inclusion of the population of children with hypertension. Besides the studies of ramipril, captopril and Trachtman et al, most of the studies concentrated on mild hypertensive patients and children with comorbidities such as severe renal impairment, renal transplantation or severe hypertension were excluded. However, children with comorbidities are known to present with more severe and therapy-resistant hypertension, which require higher doses of ACE inhibitors or combination therapy to control the BP. Furthermore, the risk of AEs (eg, hyperkalaemia) is extremely higher in children with renal impairment, renal transplantation or in children taking concomitant transplant medication (eg, tacrolimus, ciclosporin).
In addition to the previous remarks, the poor availability of labelled ACE inhibitors, indicated for the younger children (<6 years) and neonates, has to be highlighted. Among the discussed ACE inhibitors, enalapril is the only ACE inhibitor with paediatric labelling for children younger than 6 years. 28 To date, no ACE inhibitor has been evaluated by a proper conducted RCT in children younger than 6 years or neonates. For this age group, only studies with small study samples and/or poor design (retrospective, no control group) are available for captopril, lisinopril and ramipril (>3 years). The fact that there are no efficacy and/or safety studies for young children and neonates is unfortunate as most of them will have secondary forms of hypertension that may require multiple medications to achieve adequate BP control. In contrast to the other studies, the prevalence of hypotension as AE was remarkably high in the captopril studies evaluating neonates and preterm born infants. This is not surprising since neonates have a lower GFR (and thus a longer serum half-life) and the neonatal kidney is dependent on the angiotensin II postglomerular efferent arteriole vasoconstriction to maintain BP. 9 14 31 Additionally, the deleterious effects of ACE inhibitors during the second and/or third trimester of pregnancy are well described: renal tubular dysgenesis, fetal anuria leading to oligohydramnios and the Potter sequence of facial dysmorphy, limb-positioning defect and lung hypoplasia associated with skull ossification defect. 32 The question if ACE inhibition should be avoided in the immature kidney remains unanswered.
At last, the incentives did not result in an improved availability of age-appropriate formulations. Until nowadays, no suspension for ACE inhibitors is commercially available, limiting consequently a safe and child-friendly administration of these medications in the paediatric population.
Therefore, a greater effort to improve paediatric labelling is necessary, with special attention for children <6 years, neonates and children with severe renal impairment, severe hypertension or renal transplant.
CONCLUSION
The recent legislative initiatives increased the availability of paediatric labelling of ACE inhibitors. Nevertheless, many drugs used by hypertensive children have an insufficiently mapped out efficacy and safety profile and lack paediatric labelling. Moreover, many clinical questions remain and consequently complicate the selection of the most appropriate and effective ACE inhibitor in hypertensive children. The legislative initiatives also failed to fulfil several of paediatric needs: absence of longterm safety data on growth and maturation, absence of commercially available child-friendly formulations and incomplete evaluation of the entire paediatric hypertension population. Additional efforts are needed to close the gap between the availability of drugs that are labelled and indicated for paediatric use and the actual drug usage in children, especially in young children, neonates and children with severe hypertension, renal transplantation or severe renal impairment. Caution has to be taken when comparing the different ACE inhibitors (see table 1) since the study design and other study characteristics were very different. BUN, blood urea nitrogen; GFR, glomerular filtration rate.
